Cited by 1,490Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Open access

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.02.840

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC. PATIENTS AND METHODS: TRIBUTE randomly assigned patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC to erlotinib 150 mg/d or placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib. Random assignment was stratified by stage, weight loss in the previous 6 months, measurable disease, and treatment center. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response (OR), and duration of response. RESULTS: There were 1,059 assessable patients (526 erlotinib; 533 placebo). Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. Patients who reported never smoking (72 erlotinib; 44 placebo) experienced improved OS in the erlotinib arm (22.5 v 10.1 months for placebo), though no other prespecified factors showed an advantage in OS with erlotinib. Erlotinib and placebo arms were equivalent in adverse events (except rash and diarrhea). CONCLUSION: Erlotinib with concurrent carboplatin and paclitaxel did not confer a survival advantage over carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC. Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.840

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Show all 25 references

Sorted by citations

Items 601–700 of 1,000

The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer
Lilenbaum, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0097 · Cited by 26
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
Berardi, R., Santoni, M., Morgese, F., Ballatore, Savini, Onofri, Mazzanti, Pistelli, M., Pierantoni, R., Lisa, D., et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s28155 · Cited by 25
Targeted therapy: An evolving world of lung cancer
Lam, K. C., & Mok, T. S. K. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01821.x · Cited by 25
In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines
Wang, M., Liang, X., Liu, Z., Cui, J., Liu, Y., Li, J., JIANG, L.-L., MA, J.-Q., Han, L., Guo, Q., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3583 · Cited by 25
Survival following Non–Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked
Gomez, S. L., Chang, E. T., Shema, S. J., Fish, K. M., Sison, J. D., Reynolds, P., Clément-Duchêne, C., Wrensch, M., Wiencke, J. L., & Wakelee, H. A. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0965 · Cited by 25
EGFR mutations as a predictive marker of cytotoxic chemotherapy
Park, J. H., Lee, S., Keam, B., Kim, T. M., Kim, D., Yang, S.-C., Kim, Y. W., & Heo, D. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.020 · Cited by 25
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study
Chang, Q., Xu, J., Qiang, H., Teng, J., Qian, J., Lv, M., Zhang, Y., Lou, Y., Zhao, Y., Zhong, R., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.005 · Cited by 25
RETRACTED: The pharmacological and biological importance of EZH2 signaling in lung cancer
Entezari, M., Taheriazam, A., Paskeh, M. D. A., Sabouni, E., Zandieh, M. A., Aboutalebi, M., Kakavand, A., Rezaei, S., Hejazi, E. S., Saebfar, H., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114313 · Cited by 26
Retracted
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
O’Bryant, C. L., Haluska, P., Rosen, L. S., Ramanathan, R. K., Venugopal, B., Leong, S., Boinpally, R., Franke, A., Witt, K., Evans, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1733-6 · Cited by 25
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells
Morgillo, F., Martinelli, E., Troiani, T., Laus, G., Pepe, S., Gridelli, C., & Ciardiello, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0547 · Cited by 25
A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies
Chiorean, E. G., Porter, J. M., Foster, A. E., Omari, A. S. H. A., Yoder, C., Fife, K., Strother, R. M., Murry, D. J., Yu, M., Jones, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0437 · Cited by 25
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non–Small Cell Lung Carcinoma
Nakashima, K., Horita, N., Nagai, K., Manabe, S., Murakami, S., Ota, E., & Kaneko, T. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.025 · Cited by 25
Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities
Krajewski, K. M., Braschi‐Amirfarzan, M., DiPiro, P. J., Jagannathan, J. P., & Shinagare, A. B. (2017) · Korean Journal of Radiology · doi:10.3348/kjr.2017.18.1.28 · Cited by 28
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
Wen, M., Xia, J., Sun, Y., Wang, X., Fu, X., Zhang, Y., Zhang, Z., Zhou, Y., & Li, X. (2018) · Biologics · doi:10.2147/btt.s169305 · Cited by 25
Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Johnson, D. H., Blot, W. J., Carbone, D. P., González, A., Hallahan, D. E., Massion, P. P., Putnam, J. B., & Sandler, A. B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50080-4 · Cited by 25
A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer
Akerley, W., Boucher, K. M., Bentz, J. S., Arbogast, K., & Walters, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181943bb9 · Cited by 25
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials
Saijo, N., Takeuchi, M., & Kunitoh, H. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.37 · Cited by 25
Acute Fatal Liver Toxicity under Erlotinib
Schacher, S., & Pless, M. (2010) · Case Reports in Oncology · doi:10.1159/000315366 · Cited by 25
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R. J., Rakhit, A. K., Fettner, S. H., Brennscheidt, U., Feyereislova, A., & Díaz‐Rubio, E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1627 · Cited by 25
Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome
Koutsopoulos, A. V., Mavroudis, D., Dambaki, K. I., Souglakos, J., Tzortzaki, E. G., Drositis, J., Delides, G. S., Georgoulias, V., & Stathopoulos, E. N. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.009 · Cited by 25
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
Borghaei, H. (2012) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s24258 · Cited by 24
Receptor tyrosine kinase structure and function in health and disease
Karpov, O. A., Fearnley, G. W., Smith, G. A., Kankanala, J., McPherson, M. J., Tomlinson, D. C., Harrison, M. A., & Ponnambalam, S. (2015) · AIMS Biophysics · doi:10.3934/biophy.2015.4.476 · Cited by 26
Clinical Outcomes in Non-Small-Cell Lung Cancer in Relation to Expression of Predictive and Prognostic Biomarkers
Singh, N., Bal, A., Aggarwal, A. N., Das, A., & Behera, D. (2010) · Future Oncology · doi:10.2217/fon.10.30 · Cited by 24
The Role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic, and Recurrent Non-Small-Cell Lung Cancer: A Canadian National Consensus Statement
Ellis, P. M., Morzycki, W., Melosky, B. L., Butts, C., Hirsh, V., Krasnoshtein, F., Murray, N., Shepherd, F. A., Soulières, D., Tsao, M., et al. (2009) · Current Oncology · doi:10.3747/co.v16i1.393 · Cited by 24
Current status and future prospects for anti-angiogenic therapies in cancer
Staton, C. A., Brown, N. J., & Reed, M. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903196737 · Cited by 24
Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise
Azzoli, C. G., Park, B. J., Pao, W. J., Zakowski, M. F., & Kris, M. G. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815efe24 · Cited by 24
Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
Tan, P. S., Bilger, M., Lopes, G. D. L., Jr., Acharyya, S., & Haaland, B. A. (2017) · Cancer Medicine · doi:10.1002/cam4.1101 · Cited by 24
Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI
Cheong, H. T., Xu, F., Choy, C. T., Hui, C. W. C., Mok, T. S. K., & Wong, C. H. (2017) · Oncology Letters · doi:10.3892/ol.2017.7377 · Cited by 24
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
Canale, M., Pasini, L., Bronte, G., Delmonte, A., Cravero, P., Crinò, L., & Ulivi, P. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.15 · Cited by 24
Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.
Rocha‐Lima, C., & Raez, L. E. (2009) · Europe PMC (PubMed Central) · Cited by 24
Erlotinib‐Associated Acute Pneumonitis: Report of Two Cases
Vahid, B., & Esmaili, A. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/832605 · Cited by 24
Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone, T., Gridelli, C., & Ciardiello, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011beec · Cited by 24
Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non–Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor Mutation
Tsai, C., Chiu, C., Chang, K.-T., Chen, J., Lai, C.-L., Chen, Y.-M., & Hsiao, S.-Y. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318258cf17 · Cited by 24
Genetic Interactions of STAT3 and Anticancer Drug Development
Fang, B. (2014) · Cancers · doi:10.3390/cancers6010494 · Cited by 25
EGFR inhibitors in lung cancer.
Buter, J., & Giaccone, G. (2005) · PubMed · Cited by 24
Clinical biomarkers of kinase activity: examples from EGFR inhibition trials
Krause, M., & Baumann, M. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9141-z · Cited by 25
Epidermal Growth Factor Receptor-Targeted Agents for Lung Cancer
Martin, P., Kelly, C. M., & Carney, D. N. (2006) · Cancer Control · doi:10.1177/107327480601300207 · Cited by 24
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents
Escalante, C. P., Chang, Y.-C., Liao, K.-P. E., Rouleau, T., Halm, J. K., Bossi, P., Bhadriraju, S., Brito-Dellan, N., Sahai, S. K., Yusuf, S. W., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3310-3 · Cited by 24
Emerging treatment for advanced lung cancer withEGFRmutation
Inal, C., Yilmaz, E., Piperdi, B., Perez-Soler, R., & Cheng, H. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1058778 · Cited by 23
Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC
Somasundaram, A., Socinski, M. A., & Burns, T. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.971013 · Cited by 23
Clinical Approaches to Minimize Rash Associated With EGFR Inhibitors
Oishi, K. (2008) · Oncology nursing forum · doi:10.1188/08.onf.103-111 · Cited by 23
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Reguart, N. (2010) · Cancer Management and Research · doi:10.2147/cmar.s5398 · Cited by 23
The SATURN Trial: The Value of Maintenance Erlotinib in Patients with Non-Small-Cell Lung Cancer
Neal, J. W. (2010) · Future Oncology · doi:10.2217/fon.10.156 · Cited by 23
Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer
Scagliotti, G. V. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm412 · Cited by 22
Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions
Chuang, J. C., Salahudeen, A. A., & Wakelee, H. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1162786 · Cited by 23
Étude KBP-2010-CPHG : recueil des nouveaux cas de cancer bronchopulmonaire primitif diagnostiqués dans les services de pneumologie des centres hospitaliers généraux du 1er janvier au 31 décembre 2010
Grivaux, M., Locher, C., Bombaron, P., Collon, T., Coëtmeur, D., Dayen, C., Debieuvre, D., Goupil, F., Treut, J. H. L., Martin, F., et al. (2010) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2010.08.001 · Cited by 23
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
Yang, J. C., Mok, T. S. K., Han, B., Orlando, M., Puri, T., & Park, K. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.013 · Cited by 23
Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide
Larimer, B. M., Phelan, N., Wehrenberg-Klee, E. P., & Mahmood, U. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1106-6 · Cited by 23
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report
Hsieh, C.-H., Chang, H., Lin, S.-C., Chen, Y.-J., Wang, L., Hsieh, Y., Chen, C., Chong, N.-S., Lin, S. L., Chen, C.-Y., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-696 · Cited by 23
Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto, S., Fukami, T., Yagi, H., Kuroki, M., & Yotsumoto, F. (2009) · PubMed · Cited by 24
Reviewing the safety of erlotinib in non-small cell lung cancer
Reck, M., Mok, T. S. K., Wolf, J., Heigener, D. F., & Wu, Y.-L. L. C. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.540799 · Cited by 23
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer
Leung, L. K. S., Mok, T. S. K., & Loong, H. H.-F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012440015 · Cited by 23
The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas
Tsakiris, I., Soós, G., Nemes, Z., Kiss, S. S., András, C., Szántó, J., & Dezsö, B. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0304-z · Cited by 23
Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group
Agarwala, A. K., Fisher, W. B., Bruetman, D., McClean, J., Taber, D. A., Titzer, M. L., Juliar, B. E., Yu, M., Breen, T., Einhorn, L. H., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181693869 · Cited by 23
Maintenance Therapy in Advanced Non-small Cell Lung Cancer
Coate, L. E., & Shepherd, F. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d86e8b · Cited by 22
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
Alimujiang, S., Zhang, T., Han, Z.-G., Yuan, S.-F., Wang, Q., Yu, T., & Li, S. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2413 · Cited by 22
EGFR inhibition in NSCLC: New findings…. and opened questions?
Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., & Russo, A. D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.009 · Cited by 22
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
Martínez‐Martí, A., Navarro, A., & Felip, E. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.20 · Cited by 22
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
Furugaki (2010) · Oncology Reports · doi:10.3892/or_00000965 · Cited by 22
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: Chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib
Tsai, C., Chen, J., Chiu, C., Lai, C.-L., Hsiao, S.-Y., & Chang, K.-T. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.028 · Cited by 22
Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer
Cohen, V., Agulnik, J. S., Ang, C., Kasymjanova, G., Batist, G., Small, D. I., Brandao, G., Chong, G., & Miller, W. H. (2010) · Cancer · doi:10.1002/cncr.25214 · Cited by 22
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
Heymach, J. V., Lockwood, S., Herbst, R. S., Johnson, B. E., & Ryan, A. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu269 · Cited by 22
Current Trends in Cancer Therapy
Sekhon, N., Kumbla, R. A., & Mita, M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803547-4.00001-x · Cited by 23
Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice
Fiala, O., Pešek, M., Fínek, J., Krejčí, J., RICAR, J., Bortlíček, Z., Benešová, L., & Minárik, M. (2012) · Neoplasma · doi:10.4149/neo_2013_004 · Cited by 22
Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer
Johnson, D. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0095 · Cited by 22
Gefitinib (‘Iressa’): a new therapy for advanced non-small-cell lung cancer
Reck, M., & Gatzemeier, U. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.08.009 · Cited by 22
Erlotinib: Optimizing Therapy with Predictors of Response?
Goodin, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0426 · Cited by 22
Gefitinib in the treatment of advanced non-small-cell lung cancer
Reck, M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.1 · Cited by 22
Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study
de Mello, R. A., Ferreira, M., Costa, S., Costa, B. M., Pires, F. S., Neves, I., Almeida, M. I., Cunha, J., Oliveira, P., Hespanhol, V. P., et al. (2012) · Tumor Biology · doi:10.1007/s13277-012-0382-7 · Cited by 19
A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Crawford, J., Swanson, P. M., Schwarzenberger, P. O., Sandler, A. B., Prager, D., Zhang, K., Freeman, D. J., Johnson, C. W., Krishnan, K., & Johnson, D. H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a7d1da · Cited by 21
Hematologic toxicities of small molecule tyrosine kinase inhibitors
Barber, N. A., Afzal, W., & Akhtari, M. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0202-9 · Cited by 21
Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer
Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
Polo, V., & Besse, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt529 · Cited by 21
First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
Zhang, H., Chen, J., Liu, T., Dang, J., & Li, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223530 · Cited by 23
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
Santos, E. S., & Hart, L. L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s250446 · Cited by 22
Management of Patients with Advanced Non-Small Cell Lung Cancer
Triano, L. R., Deshpande, H. A., & Gettinger, S. N. (2010) · Drugs · doi:10.2165/11532200-000000000-00000 · Cited by 21
Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development
Mahalingam, D., Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.03.001 · Cited by 21
Novel insights into the molecular origins and treatment of lung cancer
Webb, J. D., & Simon, M. C. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13588 · Cited by 21
New antiangiogenetic agents and non-small cell lung cancer
Gridelli, C., Rossi, A., & Maione, P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.008 · Cited by 21
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar, R., Chénard-Poirier, M., Collins, D. C., & Yap, T. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00039 · Cited by 22
Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk
Tefurumi, K. A. T. O., & Nishio, K. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00940.x · Cited by 21
Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Carcinoma
Yoneda, K. Y., Hardin, K. A., Gandara, D. R., & Shelton, D. K. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.s.011 · Cited by 21
Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man with Lung Cancer
Pellegrinotti, M., Fimognari, F. L., Franco, A., Repetto, L., & Pastorelli, R. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l468 · Cited by 21
Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer
Mok, T. S. K., Lee, K., & Leung, L. K. S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.010 · Cited by 20
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer
Laine, A. M., Westover, K. D., & Choy, H. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.012 · Cited by 20
Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
Sequist, L. V. D., Fidias, P. M., Temel, J. S., Kolevska, T., Rabin, M. S., Boccia, R. V., Burris, H. A., Belt, R. J., Huberman, M. S., Melnyk, O. O., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b6b84b · Cited by 20
Risk of Fatal Pulmonary Events in Patients with Advanced Non-Small-Cell Lung Cancer Treated with EGF Receptor Tyrosine Kinase Inhibitors: A Comparative Meta-Analysis
Abdel-Rahman, O. M., & Elhalawani, H. M. (2015) · Future Oncology · doi:10.2217/fon.15.16 · Cited by 20
Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
Bichsel, K. J., Gogia, N., Malouff, T. D., Peña, Z. G., Forney, E., Hammiller, B., Watson, P. A., & Hansen, L. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069368 · Cited by 21
Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer
Ganti, A. K. (2010) · Cancer Investigation · doi:10.3109/07357900903476760 · Cited by 20
The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer
Socinski, M. A. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.019 · Cited by 20
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
Auliac, J. B., CHOUAID, C., Greiller, L., Monnet, I., Caer, H. L., Falchero, L., Corre, R., Descourt, R., Bota, S., Berard, H., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.006 · Cited by 20
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
Kotsakis, A. P., & Georgoulias, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498581 · Cited by 20
Translating Clinical Trials into Meaningful Outcomes
LoRusso, P. M., Schnipper, L. E., Stewart, D. J., Boerner, S. A., Averbuch, S. D., & Wolf, W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2632 · Cited by 20
Update on nonsmall cell lung cancer
Zalcman, G., Bergot, E., & Lechapt, E. (2010) · European Respiratory Review · doi:10.1183/09059180.00006610 · Cited by 20
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016
Bunn, P. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4064 · Cited by 20
Acquired Resistance in Lung Cancer
Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21
Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer
Grossi, F., Gridelli, C., Aita, M., & de Marinis, F. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.002 · Cited by 20
Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non–Small-Cell Lung Cancer
Wakelee, H. A., Kernstine, K. H., Vokes, E. E., Schiller, J. H., Baas, P., Saijo, N., Adjei, A. A., Goss, G. D., Gaspar, L. E., Gandara, D. R., et al. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.050 · Cited by 20

Authors: Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., Ramies, D., Johnson, D. H., & Miller, V. A.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Herbst, Roy S.
Johnson, Bruce E.
Sandler, Alan
Kris, Mark G.
Tran, Hai T.
Li, Xin
Ramies, David
Johnson, David H.
Miller, Vincent A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 5892-5899
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.02.840
OpenAlex: W2162724777
Cited by: 1,490
References: 25
Citations by year: 2026: 9 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 32 · 2017: 48 · 2016: 56 · 2015: 83 · 2014: 79 · 2013: 122 · 2012: 96
FWCI: 123.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: erlotinib, carboplatin, paclitaxel, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, combination chemotherapy, never smokers, overall survival, time to progression, objective response, maintenance therapy
MeSH terms: Erlotinib Hydrochloride, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Placebos, Quinazolines, Survival Analysis, Carboplatin, Paclitaxel, Disease Progression, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks